

Michele De Palma

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1977910/publications.pdf>

Version: 2024-02-01

85
papers

14,767
citations

38660

50
h-index

56606

83
g-index

87
all docs

87
docs citations

87
times ranked

21169
citing authors

#	ARTICLE	IF	CITATIONS
1	Microenvironmental regulation of tumour angiogenesis. <i>Nature Reviews Cancer</i> , 2017, 17, 457-474.	12.8	1,299
2	Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. <i>Cancer Cell</i> , 2005, 8, 211-226.	7.7	1,212
3	Macrophage Regulation of Tumor Responses to Anticancer Therapies. <i>Cancer Cell</i> , 2013, 23, 277-286.	7.7	893
4	HRG Inhibits Tumor Growth and Metastasis by Inducing Macrophage Polarization and Vessel Normalization through Downregulation of PlGF. <i>Cancer Cell</i> , 2011, 19, 31-44.	7.7	628
5	Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells. <i>Cancer Cell</i> , 2011, 19, 512-526.	7.7	543
6	Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. <i>Nature Medicine</i> , 2003, 9, 789-795.	15.2	539
7	FcR γ Activation Regulates Inflammation-Associated Squamous Carcinogenesis. <i>Cancer Cell</i> , 2010, 17, 121-134.	7.7	537
8	Endogenous RNAs Modulate MicroRNA Sorting to Exosomes and Transfer to Acceptor Cells. <i>Cell Reports</i> , 2014, 8, 1432-1446.	2.9	504
9	Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. <i>Blood</i> , 2007, 109, 5276-5285.	0.6	451
10	Consensus guidelines for the use and interpretation of angiogenesis assays. <i>Angiogenesis</i> , 2018, 21, 425-532.	3.7	429
11	Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	422
12	Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. <i>Nature Cell Biology</i> , 2019, 21, 190-202.	4.6	384
13	Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. <i>Cancer Research</i> , 2015, 75, 3479-3491.	0.4	375
14	Engineering dendritic cell vaccines to improve cancer immunotherapy. <i>Nature Communications</i> , 2019, 10, 5408.	5.8	313
15	Angiopoietin-2 Regulates Gene Expression in TIE2-Expressing Monocytes and Augments Their Inherent Proangiogenic Functions. <i>Cancer Research</i> , 2010, 70, 5270-5280.	0.4	299
16	Tumor-Targeted Interferon- β Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis. <i>Cancer Cell</i> , 2008, 14, 299-311.	7.7	267
17	Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. <i>Nature</i> , 2011, 479, 122-126.	13.7	265
18	Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. <i>Journal of Clinical Investigation</i> , 2004, 113, 1118-1129.	3.9	256

#	ARTICLE	IF	CITATIONS
19	Tie2-Expressing Monocytes and Tumor Angiogenesis: Regulation by Hypoxia and Angiopoietin-2. <i>Cancer Research</i> , 2007, 67, 8429-8432.	0.4	240
20	T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	229
21	Suppression of microRNA activity amplifies IFN- γ -induced macrophage activation and promotes anti-tumour immunity. <i>Nature Cell Biology</i> , 2016, 18, 790-802.	4.6	214
22	TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 1969-1973.	3.9	204
23	Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade. <i>Cell Reports</i> , 2014, 8, 696-706.	2.9	203
24	Epidermal Growth Factor Receptor Expression Identifies Functionally and Molecularly Distinct Tumor-Initiating Cells in Human Glioblastoma Multiforme and Is Required for Gliomagenesis. <i>Cancer Research</i> , 2010, 70, 7500-7513.	0.4	198
25	Transplanted neural stem/precursor cells instruct phagocytes and reduce secondary tissue damage in the injured spinal cord. <i>Brain</i> , 2012, 135, 447-460.	3.7	192
26	Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion. <i>Journal of Immunology</i> , 2011, 186, 4183-4190.	0.4	185
27	The interplay between macrophages and angiogenesis in development, tissue injury and regeneration. <i>International Journal of Developmental Biology</i> , 2011, 55, 495-503.	0.3	182
28	Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. <i>Blood</i> , 2005, 105, 2307-2315.	0.6	164
29	Macrophage regulation of tumor angiogenesis: Implications for cancer therapy. <i>Molecular Aspects of Medicine</i> , 2011, 32, 123-145.	2.7	152
30	Primary Human and Rat β 2-Cells Release the Intracellular Autoantigens GAD65, IA-2, and Proinsulin in Exosomes Together With Cytokine-Induced Enhancers of Immunity. <i>Diabetes</i> , 2017, 66, 460-473.	0.3	152
31	Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. <i>Journal of Experimental Medicine</i> , 2018, 215, 859-876.	4.2	150
32	Perivascular macrophages in health and disease. <i>Nature Reviews Immunology</i> , 2018, 18, 689-702.	10.6	146
33	Elusive Identities and Overlapping Phenotypes of Proangiogenic Myeloid Cells in Tumors. <i>American Journal of Pathology</i> , 2010, 176, 1564-1576.	1.9	137
34	Imaging-based spectrometer-less optofluidic biosensors based on dielectric metasurfaces for detecting extracellular vesicles. <i>Nature Communications</i> , 2021, 12, 3246.	5.8	137
35	The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities. <i>Molecular Oncology</i> , 2012, 6, 111-127.	2.1	135
36	Regulation of Macrophage Arginase Expression and Tumor Growth by the Ron Receptor Tyrosine Kinase. <i>Journal of Immunology</i> , 2011, 187, 2181-2192.	0.4	126

#	ARTICLE	IF	CITATIONS
37	Molecular Profiling and Functional Analysis of Macrophage-Derived Tumor Extracellular Vesicles. <i>Cell Reports</i> , 2019, 27, 3062-3080.e11.	2.9	118
38	In Vivo Targeting of Tumor Endothelial Cells by Systemic Delivery of Lentiviral Vectors. <i>Human Gene Therapy</i> , 2003, 14, 1193-1206.	1.4	114
39	Macrophages limit chemotherapy. <i>Nature</i> , 2011, 472, 303-304.	13.7	112
40	The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2 ^{Hi} Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2486-2501.	1.9	106
41	Systemic and Targeted Delivery of Semaphorin 3A Inhibits Tumor Angiogenesis and Progression in Mouse Tumor Models. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 741-749.	1.1	105
42	Perivascular Macrophages Limit Permeability. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2203-2212.	1.1	97
43	Proangiogenic Tie2 ⁺ Macrophages Infiltrate Human and Murine Endometriotic Lesions and Dictate Their Growth in a Mouse Model of the Disease. <i>American Journal of Pathology</i> , 2011, 179, 2651-2659.	1.9	96
44	Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis. <i>Clinical Cancer Research</i> , 2011, 17, 5226-5232.	3.2	88
45	Genetic Engineering of Hematopoiesis for Targeted IFN- γ Delivery Inhibits Breast Cancer Progression. <i>Science Translational Medicine</i> , 2014, 6, 217ra3.	5.8	86
46	Reciprocal interactions between endothelial cells and macrophages in angiogenic vascular niches. <i>Experimental Cell Research</i> , 2013, 319, 1626-1634.	1.2	85
47	TIE2-expressing monocytes/macrophages regulate revascularization of the ischemic limb. <i>EMBO Molecular Medicine</i> , 2013, 5, 858-869.	3.3	83
48	[29] Transduction of a gene expression cassette using advanced generation lentiviral vectors. <i>Methods in Enzymology</i> , 2002, 346, 514-529.	0.4	78
49	Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 541-551.	3.3	66
50	Biology and therapeutic targeting of tumour-associated macrophages. <i>Journal of Pathology</i> , 2020, 250, 573-592.	2.1	56
51	EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens. <i>Nature Methods</i> , 2018, 15, 183-186.	9.0	49
52	Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages. <i>Cancer Research</i> , 2016, 76, 3166-3178.	0.4	48
53	CD4 + T Cell Activation and Vascular Normalization: Two Sides of the Same Coin?. <i>Immunity</i> , 2017, 46, 773-775.	6.6	45
54	Reprogramming Tumor Blood Vessels for Enhancing Immunotherapy. <i>Trends in Cancer</i> , 2017, 3, 809-812.	3.8	45

#	ARTICLE	IF	CITATIONS
55	Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	44
56	PHD2 regulates arteriogenic macrophages through TIE2 signalling. <i>EMBO Molecular Medicine</i> , 2013, 5, 843-857.	3.3	40
57	A New Twist on Radiation Oncology: Low-Dose Irradiation Elicits Immunostimulatory Macrophages that Unlock Barriers to Tumor Immunotherapy. <i>Cancer Cell</i> , 2013, 24, 559-561.	7.7	36
58	<i>miR-135a</i> Inhibits Cancer Stem Cell-Driven Medulloblastoma Development by Directly Repressing <i>Arhgef6</i> Expression. <i>Stem Cells</i> , 2015, 33, 1377-1389.	1.4	35
59	<i>miR-511-3p</i> , embedded in the macrophage mannose receptor gene, contributes to intestinal inflammation. <i>Mucosal Immunology</i> , 2016, 9, 960-973.	2.7	35
60	Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice. <i>Journal of Clinical Investigation</i> , 2020, 130, 1199-1216.	3.9	35
61	Periostin Limits Tumor Response to VEGFA Inhibition. <i>Cell Reports</i> , 2018, 22, 2530-2540.	2.9	33
62	A double agent in cancer: Deciphering macrophage roles in human tumors. <i>Nature Medicine</i> , 2010, 16, 861-862.	15.2	28
63	Partners in crime: VEGF and IL-4 conscript tumour-promoting macrophages. <i>Journal of Pathology</i> , 2012, 227, 4-7.	2.1	24
64	Metastasis risk after anti-macrophage therapy. <i>Nature</i> , 2014, 515, 46-47.	13.7	24
65	Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	24
66	HS1 complexes with cytoskeleton adapters in normal and malignant chronic lymphocytic leukemia B cells. <i>Leukemia</i> , 2007, 21, 2067-2070.	3.3	22
67	A niche role for periostin and macrophages in glioblastoma. <i>Nature Cell Biology</i> , 2015, 17, 107-109.	4.6	20
68	Disentangling the complexity of tumor-derived extracellular vesicles. <i>Cell Reports</i> , 2021, 35, 108960.	2.9	20
69	Origins of Brain Tumor Macrophages. <i>Cancer Cell</i> , 2016, 30, 832-833.	7.7	18
70	Cancer Metastasis: Perivascular Macrophages Under Watch. <i>Cancer Discovery</i> , 2015, 5, 906-908.	7.7	16
71	Apelin-driven endothelial cell migration sustains intestinal progenitor cells and tumor growth. , 2022, 1, 476-490.		13
72	Circulating Endothelial Progenitors and Tumor Resistance to Vascular-Targeting Therapies. <i>Cancer Discovery</i> , 2012, 2, 395-397.	7.7	10

#	ARTICLE	IF	CITATIONS
73	TIE2-expressing monocytes: A novel cellular biomarker for hepatocellular carcinoma?. <i>Hepatology</i> , 2013, 57, 1294-1296.	3.6	10
74	Sequential Bone-Marrow Cell Delivery of VEGFA/S1P Improves Vascularization and Limits Adverse Cardiac Remodeling After Myocardial Infarction in Mice. <i>Human Gene Therapy</i> , 2019, 30, 893-905.	1.4	8
75	Macrophage interference on chemotherapy. <i>Nature Cell Biology</i> , 2019, 21, 411-412.	4.6	6
76	Boosting dendritic cell nanovaccines. <i>Nature Nanotechnology</i> , 2022, 17, 442-444.	15.6	6
77	Antagonizing metastasis. <i>Nature Biotechnology</i> , 2010, 28, 331-332.	9.4	4
78	The role of the immune system in cancer: From mechanisms to clinical applications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 1-2.	3.3	4
79	A LIGHTning Strike to the Metastatic Niche. <i>Cell Reports</i> , 2020, 30, 599-601.	2.9	3
80	DICERing macrophages for reprogramming TAMs. <i>Cell Cycle</i> , 2016, 15, 3149-3150.	1.3	2
81	Lymphoma Chemotherapy: Hungry Macrophages Strike the Final Blow. <i>Cancer Discovery</i> , 2019, 9, 834-836.	7.7	2
82	Tweaking the DNA of myeloid cells curbs cancer spread. <i>Nature</i> , 2020, 579, 196-197.	13.7	2
83	Alzheimer's drug turns macrophages against cancer. <i>Nature Cancer</i> , 2021, 2, 1119-1121.	5.7	2
84	Assessing metastasis risk after preoperative antiangiogenic therapy. <i>EMBO Molecular Medicine</i> , 2014, 6, 1515-1517.	3.3	0
85	Micromanaging restenosis by therapeutic inhibition of miR-92a. <i>Cardiovascular Research</i> , 2014, 103, 432-434.	1.8	0